A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report

BACKGROUND: Aflibercept is a novel decoy receptor that efficiently neutralizes circulating vascular endothelial growth factor (VEGF). A pediatric phase 1 trial was performed to define the dose limiting toxicities (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of aflibercept. METHODS:...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Bender, Julia Glade, Blaney, Susan M., Borinstein, Scott, Reid, Joel M., Baruchel, Sylvain, Ahern, Charlotte, Ingle, Ashish M., Yamashiro, Darrell J., Chen, Alice, Weigel, Brenda, Adamson, Peter C., Park, Julie R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3445751/
https://ncbi.nlm.nih.gov/pubmed/22791883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0078
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi